Armenia J, Wankowicz SAM, Liu D, et al. The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2018;50(5):645-651. doi:10.1038/s41588-018-0078-z.

Janouskova H, Tekle GE, Bellini E, et al. Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. Nat Med. 2017;23(9):1046-1054. doi:10.1038/nm.4372.

Escamilla CO, Filonova I, Walker AK, et al. Kctd13 deletion reduces synaptic transmission via increased RhoA. Nature. 2017;551(7679):227-231. doi:10.1038/nature24470.

Dauber A, Stoler J, Hechter E, Safer J, Hirschhorn JN. Whole exome sequencing reveals a novel mutation in CUL7 in a patient with an undiagnosed growth disorder. J Pediatr. 2013;162(1):202-4.e1. doi:10.1016/j.jpeds.2012.07.055.

Shalem O, Sanjana NE, Hartenian E, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343(6166):84-7. doi:10.1126/science.1247005.

Bakowski MA, Desjardins CA, Smelkinson MG, et al. Ubiquitin-mediated response to microsporidia and virus infection in C. elegans. PLoS Pathog. 2014;10(6):e1004200. doi:10.1371/journal.ppat.1004200.

Gan W, Dai X, Lunardi A, et al. SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression. Mol Cell. 2015;59(6):917-30. doi:10.1016/j.molcel.2015.07.026.